Table 7.

Comparison of cessation criteria for chronic hepatitis B treatment

		KASL	AASLD	EASL	APASL
NAs
	HBeAg-postive CHB	1) HBsAg loss	1) HBeAg seroconversion with 12 months consolidation plus undetectable HBV DNA	1) HBsAg loss with/without anti-HB seroconversion	1) HBeAg seroconversion with 12 months consolidation (preferably 3 years)
		2) HBeAg loss/seroconversion with 12 months consolidation plus undetectable HBV DNA	2) Alternatively, treat until HBsAg is lost	2) HBeAg seroconversion with 12 months consolidation plus undetectable HBV DNA	2) HBsAg loss or seroconversion
	HBeAg-negative CHB	1) HBsAg loss	1) Indefinite	1) HBsAg loss with/without seroconversion	1) HBsAg loss or seroconversion
			2) May be considered after HBsAg loss	2) May be considered after long-term (≥3 years) virological suppression after NA therapy	2) Undetectable HBV DNA for at least 2 years on 3 separate occasions each 6 months apart
	Liver cirrhosis	1) Long-term treatment for compensated cirrhosis	1) Indefinite (may be considered after HBsAg loss)	1) Indefinite	1) NA therapy should be continued for life in compensated and decompensated cirrhotic patients
		2) Indefinite for decompensated cirrhosis
Peg-Interferon
	HBeAg (+)	48 weeks	48 weeks	48 weeks	48 weeks
	HBeAg (-)	48 weeks	48 weeks	1) 48 weeks	48 weeks
				2) Extending treatment beyond 48 weeks may be beneficial

1) Preferred, 2) alternative.

KASL, Korean Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; APASL, Asian-Pacific Association for the Study of the Liver; NA, nucleos(t)ide analog; HBeAg, hepatitis B e antigen; CHB, chronic hepatitis B; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; peg-interferon, pegylated interferon.